SG11201707427TA - Morphinan derivative - Google Patents

Morphinan derivative

Info

Publication number
SG11201707427TA
SG11201707427TA SG11201707427TA SG11201707427TA SG11201707427TA SG 11201707427T A SG11201707427T A SG 11201707427TA SG 11201707427T A SG11201707427T A SG 11201707427TA SG 11201707427T A SG11201707427T A SG 11201707427TA SG 11201707427T A SG11201707427T A SG 11201707427TA
Authority
SG
Singapore
Prior art keywords
morphinan derivative
morphinan
derivative
Prior art date
Application number
SG11201707427TA
Other languages
English (en)
Inventor
Hiroshi Nagase
Hideaki Fujii
Akiyoshi Saitoh
Eriko Nakata
Masaaki Hirose
Isao Ooi
Kohei Hayashida
Original Assignee
Univ Tsukuba
School Juridical Person Kitasato Inst
Nat Center Neurology & Psychiatry
Nippon Chemiphar Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56919074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201707427T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Tsukuba, School Juridical Person Kitasato Inst, Nat Center Neurology & Psychiatry, Nippon Chemiphar Co filed Critical Univ Tsukuba
Publication of SG11201707427TA publication Critical patent/SG11201707427TA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11201707427TA 2015-03-17 2016-03-17 Morphinan derivative SG11201707427TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015054079 2015-03-17
PCT/JP2016/058475 WO2016148232A1 (fr) 2015-03-17 2016-03-17 Dérivé de morphinane

Publications (1)

Publication Number Publication Date
SG11201707427TA true SG11201707427TA (en) 2017-10-30

Family

ID=56919074

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201707427TA SG11201707427TA (en) 2015-03-17 2016-03-17 Morphinan derivative
SG10201907667RA SG10201907667RA (en) 2015-03-17 2016-03-17 Morphinan derivative

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201907667RA SG10201907667RA (en) 2015-03-17 2016-03-17 Morphinan derivative

Country Status (24)

Country Link
US (4) US10442802B2 (fr)
EP (2) EP3974430A1 (fr)
JP (4) JP6692345B2 (fr)
KR (2) KR102551969B1 (fr)
CN (3) CN107614500B (fr)
AU (2) AU2016234222C1 (fr)
BR (1) BR112017019805B1 (fr)
CA (1) CA2979023C (fr)
CY (1) CY1124908T1 (fr)
DK (1) DK3272750T3 (fr)
ES (1) ES2904511T3 (fr)
HK (1) HK1249900A1 (fr)
HU (1) HUE057266T2 (fr)
IL (1) IL254473B (fr)
MA (1) MA41790B1 (fr)
MX (2) MX2017011824A (fr)
MY (1) MY197742A (fr)
PH (1) PH12017501655A1 (fr)
PL (1) PL3272750T3 (fr)
RU (1) RU2762567C2 (fr)
SG (2) SG11201707427TA (fr)
TW (2) TWI775723B (fr)
WO (1) WO2016148232A1 (fr)
ZA (1) ZA201706882B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018030382A1 (fr) 2016-08-09 2018-02-15 国立大学法人 筑波大学 Dérivé de morphinane
CA3040445A1 (fr) * 2016-09-16 2018-03-22 Nippon Chemiphar Co., Ltd. Utilisation de derives de morphinane pour le traitement de maladies associees a un agoniste des recepteurs opioides d
WO2018066532A1 (fr) * 2016-10-03 2018-04-12 学校法人 星薬科大学 Composition pharmaceutique contenant un dérivé de morphinane et son utilisation en tant qu'analgésique
CA3147221A1 (fr) * 2019-07-19 2021-01-28 Nippon Chemiphar Co., Ltd. Procede de production d'un derive du phenol
KR20220035383A (ko) 2019-07-19 2022-03-22 닛뽕 케미파 가부시키가이샤 모르피난 유도체의 제조 방법
CN115989028A (zh) 2020-08-28 2023-04-18 日本化学药品株式会社 使用新的铜催化剂制备具有二芳基醚骨架的吗啡喃衍生物的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005231995A (ja) 1999-12-22 2005-09-02 Meiji Seika Kaisha Ltd オピオイドδ受容体アゴニスト/アンタゴニストとして有用なスピロ化合物
DE10161963A1 (de) 2001-12-17 2003-07-03 Johannes Schuetz 6-Aminomorphinanderivate, Herstellungsverfahren dafür und deren Verwendung
CL2004000754A1 (es) 2003-04-11 2005-02-25 Janssen Pharmaceutica Nv Uso de compuestos derivados de 4-fenil-4-(1h-imidazol-2-il)piperidina, como agonistas delta-opioides no peptidicos, para preparar un medicamento util en prevenir o tratar trastornos del sistema nervioso central.
CN101155812A (zh) 2005-04-04 2008-04-02 阿斯利康(瑞典)有限公司 新二氮杂螺烷和它们治疗ccr8介导的疾病的用途
JPWO2008001859A1 (ja) 2006-06-30 2009-11-26 学校法人北里研究所 オピオイドδ受容体アゴニスト
US20110130406A1 (en) 2007-09-06 2011-06-02 Array Biopharma Inc. Pyrazolo-pyridines as tyrosine kinase inhibitors
AU2010313392B2 (en) 2009-10-30 2015-07-09 Janssen Pharmaceutica Nv Pyrazines as delta opioid receptor modulators
WO2011090935A1 (fr) 2010-01-19 2011-07-28 Merck Sharp & Dohme Corp. Composés pyrazolo[1,5-a]pyrimidines en tant qu'inhibiteurs de mtor
EP2655332B1 (fr) 2010-12-23 2016-07-13 Phoenix Pharmalabs, Inc. Nouveaux morphinanes utiles en tant qu'analgésiques
JP2014073964A (ja) 2011-01-28 2014-04-24 Kitasato Institute モルヒナン誘導体
US8952030B2 (en) * 2011-09-09 2015-02-10 The Kitasato Institute Morphinan derivative
WO2014021273A1 (fr) * 2012-07-30 2014-02-06 学校法人北里研究所 Dérivés morphinane
US8937084B2 (en) 2012-12-14 2015-01-20 Purdue Pharma L.P. Nitrogen containing morphinan derivatives and the use thereof
CA2908805A1 (fr) * 2013-03-08 2014-09-12 The Kitasato Institute Derive de morphinane
CA3040445A1 (fr) 2016-09-16 2018-03-22 Nippon Chemiphar Co., Ltd. Utilisation de derives de morphinane pour le traitement de maladies associees a un agoniste des recepteurs opioides d

Also Published As

Publication number Publication date
KR102551969B1 (ko) 2023-07-05
AU2020270503C9 (en) 2024-02-29
TWI778933B (zh) 2022-09-21
ES2904511T3 (es) 2022-04-05
US20200079775A1 (en) 2020-03-12
RU2017134286A (ru) 2019-04-05
ZA201706882B (en) 2022-02-23
US20210040094A1 (en) 2021-02-11
JP2024010098A (ja) 2024-01-23
HK1249900A1 (zh) 2018-11-16
JP7375076B2 (ja) 2023-11-07
SG10201907667RA (en) 2019-09-27
IL254473B (en) 2022-05-01
JP2022081656A (ja) 2022-05-31
US10442802B2 (en) 2019-10-15
BR112017019805A2 (pt) 2018-05-29
AU2020270503A1 (en) 2020-12-17
TWI775723B (zh) 2022-09-01
TW202244044A (zh) 2022-11-16
PH12017501655B1 (en) 2018-03-12
EP3974430A1 (fr) 2022-03-30
AU2020270503B9 (en) 2023-10-12
KR20180002616A (ko) 2018-01-08
DK3272750T3 (en) 2022-01-03
EP3272750A4 (fr) 2018-08-08
AU2020270503B2 (en) 2023-02-02
CN113292559B (zh) 2024-04-02
TW201638089A (zh) 2016-11-01
AU2020270503C1 (en) 2023-08-10
PL3272750T3 (pl) 2022-03-07
WO2016148232A1 (fr) 2016-09-22
US11643411B2 (en) 2023-05-09
CN113292558A (zh) 2021-08-24
US20180057493A1 (en) 2018-03-01
AU2016234222C1 (en) 2021-02-11
US10995092B2 (en) 2021-05-04
RU2762567C2 (ru) 2021-12-21
JP2020117533A (ja) 2020-08-06
JP6692345B2 (ja) 2020-05-13
EP3272750B1 (fr) 2021-11-03
AU2016234222B2 (en) 2020-08-27
RU2017134286A3 (fr) 2019-04-19
MX2017011824A (es) 2018-04-20
MX2021008741A (es) 2022-11-01
IL254473A0 (en) 2017-11-30
AU2016234222A1 (en) 2017-10-26
HUE057266T2 (hu) 2022-05-28
MA41790B1 (fr) 2022-02-28
JPWO2016148232A1 (ja) 2018-03-08
CA2979023A1 (fr) 2016-09-22
MY197742A (en) 2023-07-12
MA41790A (fr) 2021-06-02
US20230159530A1 (en) 2023-05-25
CA2979023C (fr) 2023-09-26
CN113292559A (zh) 2021-08-24
CY1124908T1 (el) 2023-01-05
CN107614500A (zh) 2018-01-19
BR112017019805B1 (pt) 2023-01-31
CN107614500B (zh) 2021-06-15
EP3272750A1 (fr) 2018-01-24
PH12017501655A1 (en) 2018-03-12
KR20230104767A (ko) 2023-07-10

Similar Documents

Publication Publication Date Title
HK1255045A1 (zh) 取代的氧代吡啶衍生物
IL253381A0 (en) History of h9-pyrrolo-dipyridine
LT3204359T (lt) Tetrahidroizochinolino dariniai
ZA201704602B (en) Dihydroindolizinone derivative
HK1245258A1 (zh) 新的二氟酮酰胺衍生物
HK1249900A1 (zh) 嗎啡喃衍生物
AP2016009530A0 (en) Cycloalkyl-linked diheterocycle derivatives
IL251005B (en) Pyrido-oxazinone derivatives
IL248772A0 (en) A consequence of cyclohexyl pyridine
GB2537912B (en) Anti-ligature bracket
HK1259107A1 (zh) 氨基唑衍生物
SG10201510721SA (en) Bracket
GB2533834B (en) Locator
GB201510068D0 (en) Flexi-wing bracket
GB201508516D0 (en) Bracket
AU361522S (en) Bracket